Optimal antithrombotic strategy following valve-in-valve transcatheter aortic and mitral valve replacement.

ABSTRACT: The treatment of aortic and mitral valve disease requiring replacement has shifted to an increasing use of bioprosthetic heart valves. Due to their limited durability, there is a growing need for reintervention in the setting of failing bioprosthesis. Even though the gold standard for the treatment of failed bioprosthesis remains surgical repair or replacement, valve-in-valve (ViV) transcatheter aortic and mitral valve replacement have emerged as safe and effective alternatives for patients who are at high or prohibitive risk for surgery. Both procedures are associated with a substantial risk of postprocedural thromboembolic events and valvular thrombosis that is often higher than transcatheter replacement of native valves. With guidelines lacking specific protocols and a limited number of

SUBMITTER: Reisinger M 

PROVIDER: S-EPMC10944778 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature